-
Soluble CD87 (s-uPAR) predicts bevacizumab-based first line treatment of metastatic colorectal cancer (mCRC): results from a prospective multi-center study
-
Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us
-
Dynamic biomarkers of response to antiangiogenic therapies in colorectal cancer: a review
-
Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars
-
(
YeYWangMWangB, et al
CD98, a potential diagnostic cancer-related biomarker, and its prognostic impact in colorectal cancer patients. Int J Clin Exp Pathol
2017; 10: 5418–5429.)
YeYWangMWangB, et al
CD98, a potential diagnostic cancer-related biomarker, and its prognostic impact in colorectal cancer patients. Int J Clin Exp Pathol
2017; 10: 5418–5429.
YeYWangMWangB, et al
CD98, a potential diagnostic cancer-related biomarker, and its prognostic impact in colorectal cancer patients. Int J Clin Exp Pathol
2017; 10: 5418–5429.,
YeYWangMWangB, et al
CD98, a potential diagnostic cancer-related biomarker, and its prognostic impact in colorectal cancer patients. Int J Clin Exp Pathol
2017; 10: 5418–5429.
-
αV integrins in angiogenesis and cancer
-
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer
-
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
-
(
Des GuetzGUzzanBNicolasP, et al
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer
2006; 94: 1823–1832.16773076)
Des GuetzGUzzanBNicolasP, et al
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer
2006; 94: 1823–1832.16773076
Des GuetzGUzzanBNicolasP, et al
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer
2006; 94: 1823–1832.16773076,
Des GuetzGUzzanBNicolasP, et al
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer
2006; 94: 1823–1832.16773076
-
CD98hc (SLC3A2), a novel marker in renal cell cancer
-
(
BrayFFerlayJSoerjomataramI, et al
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
2018; 68: 394–424.30207593)
BrayFFerlayJSoerjomataramI, et al
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
2018; 68: 394–424.30207593
BrayFFerlayJSoerjomataramI, et al
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
2018; 68: 394–424.30207593,
BrayFFerlayJSoerjomataramI, et al
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
2018; 68: 394–424.30207593
-
(
MohamedSYMohammedHLIbrahimHM, et al
Role of VEGF, CD105, and CD31 in the prognosis of colorectal cancer cases. J Gastrointest Cancer
2019; 50: 23–34.29110224)
MohamedSYMohammedHLIbrahimHM, et al
Role of VEGF, CD105, and CD31 in the prognosis of colorectal cancer cases. J Gastrointest Cancer
2019; 50: 23–34.29110224
MohamedSYMohammedHLIbrahimHM, et al
Role of VEGF, CD105, and CD31 in the prognosis of colorectal cancer cases. J Gastrointest Cancer
2019; 50: 23–34.29110224,
MohamedSYMohammedHLIbrahimHM, et al
Role of VEGF, CD105, and CD31 in the prognosis of colorectal cancer cases. J Gastrointest Cancer
2019; 50: 23–34.29110224
-
(
Rodriguez-PascualJCubilloA.
Dynamic biomarkers of response to antiangiogenic therapies in colorectal cancer: a review. Curr Pharmacogenomics Person Med
2017; 15: 81–85.29657584)
Rodriguez-PascualJCubilloA.
Dynamic biomarkers of response to antiangiogenic therapies in colorectal cancer: a review. Curr Pharmacogenomics Person Med
2017; 15: 81–85.29657584
Rodriguez-PascualJCubilloA.
Dynamic biomarkers of response to antiangiogenic therapies in colorectal cancer: a review. Curr Pharmacogenomics Person Med
2017; 15: 81–85.29657584,
Rodriguez-PascualJCubilloA.
Dynamic biomarkers of response to antiangiogenic therapies in colorectal cancer: a review. Curr Pharmacogenomics Person Med
2017; 15: 81–85.29657584
-
(
HlatkyLHahnfeldtPFolkmanJ
Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst
2002; 94: 883–893.12072542)
HlatkyLHahnfeldtPFolkmanJ
Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst
2002; 94: 883–893.12072542
HlatkyLHahnfeldtPFolkmanJ
Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst
2002; 94: 883–893.12072542,
HlatkyLHahnfeldtPFolkmanJ
Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst
2002; 94: 883–893.12072542
-
Neuropilins controlling cancer therapy responsiveness
-
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
-
(
UnseldMKornekGGleissA, et al
Soluble CD87 (s-uPAR) predicts bevacizumab-based first line treatment of metastatic colorectal cancer (mCRC): results from a prospective multi-center study. J Clin Oncol
2017; 35(Suppl. 4): Abstract 604.)
UnseldMKornekGGleissA, et al
Soluble CD87 (s-uPAR) predicts bevacizumab-based first line treatment of metastatic colorectal cancer (mCRC): results from a prospective multi-center study. J Clin Oncol
2017; 35(Suppl. 4): Abstract 604.
UnseldMKornekGGleissA, et al
Soluble CD87 (s-uPAR) predicts bevacizumab-based first line treatment of metastatic colorectal cancer (mCRC): results from a prospective multi-center study. J Clin Oncol
2017; 35(Suppl. 4): Abstract 604.,
UnseldMKornekGGleissA, et al
Soluble CD87 (s-uPAR) predicts bevacizumab-based first line treatment of metastatic colorectal cancer (mCRC): results from a prospective multi-center study. J Clin Oncol
2017; 35(Suppl. 4): Abstract 604.
-
(
VermeulenPBVan den EyndenGGHugetP, et al
Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer
1999; 79: 316–322.9888475)
VermeulenPBVan den EyndenGGHugetP, et al
Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer
1999; 79: 316–322.9888475
VermeulenPBVan den EyndenGGHugetP, et al
Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer
1999; 79: 316–322.9888475,
VermeulenPBVan den EyndenGGHugetP, et al
Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer
1999; 79: 316–322.9888475
-
(
The ASCO Post. FDA approves bevacizumab biosimilar for five cancer types, https://www.ascopost.com/News/60204 (2019, accessed 18 July 2019).)
The ASCO Post. FDA approves bevacizumab biosimilar for five cancer types, https://www.ascopost.com/News/60204 (2019, accessed 18 July 2019).
The ASCO Post. FDA approves bevacizumab biosimilar for five cancer types, https://www.ascopost.com/News/60204 (2019, accessed 18 July 2019).,
The ASCO Post. FDA approves bevacizumab biosimilar for five cancer types, https://www.ascopost.com/News/60204 (2019, accessed 18 July 2019).
-
(
StintzingSFischer von WeikersthalLDeckerT, et al
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol
2012; 23: 1693–1699.22219013)
StintzingSFischer von WeikersthalLDeckerT, et al
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol
2012; 23: 1693–1699.22219013
StintzingSFischer von WeikersthalLDeckerT, et al
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol
2012; 23: 1693–1699.22219013,
StintzingSFischer von WeikersthalLDeckerT, et al
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol
2012; 23: 1693–1699.22219013
-
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
-
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
-
PTEN status in advanced colorectal cancer treated with cetuximab
-
Role of integrins in resistance to therapies targeting growth factor receptors in cancer
-
Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study
-
(
NapolitanoVTamagnoneL.
Neuropilins controlling cancer therapy responsiveness. Int J Mol Sci
2019; 20: 2049.)
NapolitanoVTamagnoneL.
Neuropilins controlling cancer therapy responsiveness. Int J Mol Sci
2019; 20: 2049.
NapolitanoVTamagnoneL.
Neuropilins controlling cancer therapy responsiveness. Int J Mol Sci
2019; 20: 2049.,
NapolitanoVTamagnoneL.
Neuropilins controlling cancer therapy responsiveness. Int J Mol Sci
2019; 20: 2049.
-
About Avastin: proposed mechanism of action
-
Angiogenesis in cancer: anti-VEGF escape mechanisms
-
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial
-
(
ZhangWAzumaMLurjeG, et al
Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res
2010; 30: 4209–4217.21036743)
ZhangWAzumaMLurjeG, et al
Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res
2010; 30: 4209–4217.21036743
ZhangWAzumaMLurjeG, et al
Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res
2010; 30: 4209–4217.21036743,
ZhangWAzumaMLurjeG, et al
Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res
2010; 30: 4209–4217.21036743
-
(
ChangLC
The biosimilar pathway in the USA: an analysis of the innovator company and biosimilar company perspectives and beyond. J Food Drug Anal
2019; 27: 671–678.31324283)
ChangLC
The biosimilar pathway in the USA: an analysis of the innovator company and biosimilar company perspectives and beyond. J Food Drug Anal
2019; 27: 671–678.31324283
ChangLC
The biosimilar pathway in the USA: an analysis of the innovator company and biosimilar company perspectives and beyond. J Food Drug Anal
2019; 27: 671–678.31324283,
ChangLC
The biosimilar pathway in the USA: an analysis of the innovator company and biosimilar company perspectives and beyond. J Food Drug Anal
2019; 27: 671–678.31324283
-
(
SokerSTakashimaSMiaoHQ, et al
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell
1998; 92: 735–745.9529250)
SokerSTakashimaSMiaoHQ, et al
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell
1998; 92: 735–745.9529250
SokerSTakashimaSMiaoHQ, et al
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell
1998; 92: 735–745.9529250,
SokerSTakashimaSMiaoHQ, et al
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell
1998; 92: 735–745.9529250
-
(
SeoNPolozovaAZhangM, et al
Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. MAbs
2018; 10: 678–691.29553864)
SeoNPolozovaAZhangM, et al
Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. MAbs
2018; 10: 678–691.29553864
SeoNPolozovaAZhangM, et al
Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. MAbs
2018; 10: 678–691.29553864,
SeoNPolozovaAZhangM, et al
Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. MAbs
2018; 10: 678–691.29553864
-
MAVERICC, a randomized, biomarker-stratified, phase II study of mFOLFOX6-bevacizumab versus FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer
-
Annual report to the nation on the status of cancer, 1975–2014, featuring survival
-
CD98hc facilitates B cell proliferation and adaptive humoral immunity
-
(
CiomborKKWuCGoldbergRM.
Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med
2015; 66: 83–95.25341011)
CiomborKKWuCGoldbergRM.
Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med
2015; 66: 83–95.25341011
CiomborKKWuCGoldbergRM.
Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med
2015; 66: 83–95.25341011,
CiomborKKWuCGoldbergRM.
Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med
2015; 66: 83–95.25341011
-
(
JubbAMHurwitzHIBaiW, et al
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol
2006; 24: 217–227.16365183)
JubbAMHurwitzHIBaiW, et al
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol
2006; 24: 217–227.16365183
JubbAMHurwitzHIBaiW, et al
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol
2006; 24: 217–227.16365183,
JubbAMHurwitzHIBaiW, et al
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol
2006; 24: 217–227.16365183
-
(
Van CutsemECervantesAAdamR, et al
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol
2016; 27: 1386–1422.27380959)
Van CutsemECervantesAAdamR, et al
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol
2016; 27: 1386–1422.27380959
Van CutsemECervantesAAdamR, et al
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol
2016; 27: 1386–1422.27380959,
Van CutsemECervantesAAdamR, et al
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol
2016; 27: 1386–1422.27380959
-
(
CruzdaSilvaEDontenwillMChoulierL, et al
Role of integrins in resistance to therapies targeting growth factor receptors in cancer. Cancers (Basel)
2019; 11: 692.)
CruzdaSilvaEDontenwillMChoulierL, et al
Role of integrins in resistance to therapies targeting growth factor receptors in cancer. Cancers (Basel)
2019; 11: 692.
CruzdaSilvaEDontenwillMChoulierL, et al
Role of integrins in resistance to therapies targeting growth factor receptors in cancer. Cancers (Basel)
2019; 11: 692.,
CruzdaSilvaEDontenwillMChoulierL, et al
Role of integrins in resistance to therapies targeting growth factor receptors in cancer. Cancers (Basel)
2019; 11: 692.
-
Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer
-
(
GoodmanL.
Persistence–luck–Avastin. J Clin Invest
2004; 113: 934.15057295)
GoodmanL.
Persistence–luck–Avastin. J Clin Invest
2004; 113: 934.15057295
GoodmanL.
Persistence–luck–Avastin. J Clin Invest
2004; 113: 934.15057295,
GoodmanL.
Persistence–luck–Avastin. J Clin Invest
2004; 113: 934.15057295
-
(
WeisSMChereshDA
αV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med
2011; 1: a006478.22229119)
WeisSMChereshDA
αV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med
2011; 1: a006478.22229119
WeisSMChereshDA
αV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med
2011; 1: a006478.22229119,
WeisSMChereshDA
αV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med
2011; 1: a006478.22229119
-
(
JemalAWardEMJohnsonCJ, et al
Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst
2017; 109: djx030.)
JemalAWardEMJohnsonCJ, et al
Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst
2017; 109: djx030.
JemalAWardEMJohnsonCJ, et al
Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst
2017; 109: djx030.,
JemalAWardEMJohnsonCJ, et al
Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst
2017; 109: djx030.
-
European cancer mortality predictions for the year 2019 with focus on breast cancer
-
(
BoonstraMCVerbeekFPMazarAP, et al
Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study. BMC cancer
2014; 14: 269.24742002)
BoonstraMCVerbeekFPMazarAP, et al
Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study. BMC cancer
2014; 14: 269.24742002
BoonstraMCVerbeekFPMazarAP, et al
Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study. BMC cancer
2014; 14: 269.24742002,
BoonstraMCVerbeekFPMazarAP, et al
Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study. BMC cancer
2014; 14: 269.24742002
-
(
MalvezziMCarioliGBertuccioP, et al
European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol
2019; 30: 781–787.30887043)
MalvezziMCarioliGBertuccioP, et al
European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol
2019; 30: 781–787.30887043
MalvezziMCarioliGBertuccioP, et al
European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol
2019; 30: 781–787.30887043,
MalvezziMCarioliGBertuccioP, et al
European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol
2019; 30: 781–787.30887043
-
(
RosenLSJacobsIABurkesRL
Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol
2017; 12: 599–610.28801849)
RosenLSJacobsIABurkesRL
Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol
2017; 12: 599–610.28801849
RosenLSJacobsIABurkesRL
Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol
2017; 12: 599–610.28801849,
RosenLSJacobsIABurkesRL
Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol
2017; 12: 599–610.28801849
-
(
Avastin® (bevacizumab). Prescribing information. Genentech, Inc, South San Francisco, CA, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125085s317lbl.pdf. (accessed December 2016).)
Avastin® (bevacizumab). Prescribing information. Genentech, Inc, South San Francisco, CA, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125085s317lbl.pdf. (accessed December 2016).
Avastin® (bevacizumab). Prescribing information. Genentech, Inc, South San Francisco, CA, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125085s317lbl.pdf. (accessed December 2016).,
Avastin® (bevacizumab). Prescribing information. Genentech, Inc, South San Francisco, CA, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125085s317lbl.pdf. (accessed December 2016).
-
The biosimilar pathway in the USA: an analysis of the innovator company and biosimilar company perspectives and beyond
-
(
FeralCCNishiyaNFenczikCA, et al
CD98hc (SLC3A2) mediates integrin signaling. Proc Natl Acad Sci U S A
2005; 102: 355–360.15625115)
FeralCCNishiyaNFenczikCA, et al
CD98hc (SLC3A2) mediates integrin signaling. Proc Natl Acad Sci U S A
2005; 102: 355–360.15625115
FeralCCNishiyaNFenczikCA, et al
CD98hc (SLC3A2) mediates integrin signaling. Proc Natl Acad Sci U S A
2005; 102: 355–360.15625115,
FeralCCNishiyaNFenczikCA, et al
CD98hc (SLC3A2) mediates integrin signaling. Proc Natl Acad Sci U S A
2005; 102: 355–360.15625115
-
Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab
-
Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study)
-
Distinct domains of CD98hc regulate integrins and amino acid transport
-
(
ParikhARLeeFCYauL, et al
MAVERICC, a randomized, biomarker-stratified, phase II study of mFOLFOX6-bevacizumab versus FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer. Clin Cancer Res
2019; 25: 2988–2995.30224341)
ParikhARLeeFCYauL, et al
MAVERICC, a randomized, biomarker-stratified, phase II study of mFOLFOX6-bevacizumab versus FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer. Clin Cancer Res
2019; 25: 2988–2995.30224341
ParikhARLeeFCYauL, et al
MAVERICC, a randomized, biomarker-stratified, phase II study of mFOLFOX6-bevacizumab versus FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer. Clin Cancer Res
2019; 25: 2988–2995.30224341,
ParikhARLeeFCYauL, et al
MAVERICC, a randomized, biomarker-stratified, phase II study of mFOLFOX6-bevacizumab versus FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer. Clin Cancer Res
2019; 25: 2988–2995.30224341
-
(
RodriguezSHuynh-DoU.
The role of PTEN in tumor angiogenesis. J Oncol
2012; 2012: 141236.21904550)
RodriguezSHuynh-DoU.
The role of PTEN in tumor angiogenesis. J Oncol
2012; 2012: 141236.21904550
RodriguezSHuynh-DoU.
The role of PTEN in tumor angiogenesis. J Oncol
2012; 2012: 141236.21904550,
RodriguezSHuynh-DoU.
The role of PTEN in tumor angiogenesis. J Oncol
2012; 2012: 141236.21904550
-
(
PragerGWPoettlerMUnseldM, et al
Angiogenesis in cancer: anti-VEGF escape mechanisms. Transl Lung Cancer Res
2012; 1: 14–25.25806151)
PragerGWPoettlerMUnseldM, et al
Angiogenesis in cancer: anti-VEGF escape mechanisms. Transl Lung Cancer Res
2012; 1: 14–25.25806151
PragerGWPoettlerMUnseldM, et al
Angiogenesis in cancer: anti-VEGF escape mechanisms. Transl Lung Cancer Res
2012; 1: 14–25.25806151,
PragerGWPoettlerMUnseldM, et al
Angiogenesis in cancer: anti-VEGF escape mechanisms. Transl Lung Cancer Res
2012; 1: 14–25.25806151
-
Recent therapeutic advances in the treatment of colorectal cancer
-
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
-
CD98hc (SLC3A2) mediates integrin signaling
-
Prescribing information
-
SERPINB7 expression predicts poor pancreatic cancer survival upon gemcitabine treatment
-
Role of VEGF, CD105, and CD31 in the prognosis of colorectal cancer cases
-
(
FenczikCAZentRDellosM, et al
Distinct domains of CD98hc regulate integrins and amino acid transport. J Biol Chem
2001; 276: 8746–8752.11121428)
FenczikCAZentRDellosM, et al
Distinct domains of CD98hc regulate integrins and amino acid transport. J Biol Chem
2001; 276: 8746–8752.11121428
FenczikCAZentRDellosM, et al
Distinct domains of CD98hc regulate integrins and amino acid transport. J Biol Chem
2001; 276: 8746–8752.11121428,
FenczikCAZentRDellosM, et al
Distinct domains of CD98hc regulate integrins and amino acid transport. J Biol Chem
2001; 276: 8746–8752.11121428
-
Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses
-
VEGF, Flt-1, and microvessel density in primary tumors as predictive factors of colorectal cancer prognosis
-
Persistence–luck–Avastin
-
The role of PTEN in tumor angiogenesis
-
CD98, a potential diagnostic cancer-related biomarker, and its prognostic impact in colorectal cancer patients
-
(
CantorJBrowneCDRuppertR, et al
CD98hc facilitates B cell proliferation and adaptive humoral immunity. Nat Immunol
2009; 10: 412–419.19270713)
CantorJBrowneCDRuppertR, et al
CD98hc facilitates B cell proliferation and adaptive humoral immunity. Nat Immunol
2009; 10: 412–419.19270713
CantorJBrowneCDRuppertR, et al
CD98hc facilitates B cell proliferation and adaptive humoral immunity. Nat Immunol
2009; 10: 412–419.19270713,
CantorJBrowneCDRuppertR, et al
CD98hc facilitates B cell proliferation and adaptive humoral immunity. Nat Immunol
2009; 10: 412–419.19270713
-
(
BianconiDHeracMSpiesD, et al
SERPINB7 expression predicts poor pancreatic cancer survival upon gemcitabine treatment. Transl Oncol
2019; 12: 15–23.30245304)
BianconiDHeracMSpiesD, et al
SERPINB7 expression predicts poor pancreatic cancer survival upon gemcitabine treatment. Transl Oncol
2019; 12: 15–23.30245304
BianconiDHeracMSpiesD, et al
SERPINB7 expression predicts poor pancreatic cancer survival upon gemcitabine treatment. Transl Oncol
2019; 12: 15–23.30245304,
BianconiDHeracMSpiesD, et al
SERPINB7 expression predicts poor pancreatic cancer survival upon gemcitabine treatment. Transl Oncol
2019; 12: 15–23.30245304
-
(
HeinemannVvon WeikersthalLFDeckerT, et al
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol
2014; 15: 1065–1075.25088940)
HeinemannVvon WeikersthalLFDeckerT, et al
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol
2014; 15: 1065–1075.25088940
HeinemannVvon WeikersthalLFDeckerT, et al
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol
2014; 15: 1065–1075.25088940,
HeinemannVvon WeikersthalLFDeckerT, et al
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol
2014; 15: 1065–1075.25088940
-
The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style
-
(
Avastin® (bevacizumab). About Avastin: proposed mechanism of action. Genentech, Inc.: South San Francisco, CA, https://www.avastin.com/hcp/mcrc/proposed-moa.html (Accessed 04 April 2019).)
Avastin® (bevacizumab). About Avastin: proposed mechanism of action. Genentech, Inc.: South San Francisco, CA, https://www.avastin.com/hcp/mcrc/proposed-moa.html (Accessed 04 April 2019).
Avastin® (bevacizumab). About Avastin: proposed mechanism of action. Genentech, Inc.: South San Francisco, CA, https://www.avastin.com/hcp/mcrc/proposed-moa.html (Accessed 04 April 2019).,
Avastin® (bevacizumab). About Avastin: proposed mechanism of action. Genentech, Inc.: South San Francisco, CA, https://www.avastin.com/hcp/mcrc/proposed-moa.html (Accessed 04 April 2019).
-
(
Van CutsemEde HaasSKangYK, et al
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol
2012; 30: 2119–2127.22565005)
Van CutsemEde HaasSKangYK, et al
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol
2012; 30: 2119–2127.22565005
Van CutsemEde HaasSKangYK, et al
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol
2012; 30: 2119–2127.22565005,
Van CutsemEde HaasSKangYK, et al
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol
2012; 30: 2119–2127.22565005
-
(
MargheriFLucianiCTaddeiML, et al
The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style. Oncotarget
2014; 5: 1538–1553.24681666)
MargheriFLucianiCTaddeiML, et al
The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style. Oncotarget
2014; 5: 1538–1553.24681666
MargheriFLucianiCTaddeiML, et al
The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style. Oncotarget
2014; 5: 1538–1553.24681666,
MargheriFLucianiCTaddeiML, et al
The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style. Oncotarget
2014; 5: 1538–1553.24681666
-
(
PragerGWPoettlerMSchmidingerM, et al
CD98hc (SLC3A2), a novel marker in renal cell cancer. Eur J Clin Invest
2009; 39: 304–310.19292886)
PragerGWPoettlerMSchmidingerM, et al
CD98hc (SLC3A2), a novel marker in renal cell cancer. Eur J Clin Invest
2009; 39: 304–310.19292886
PragerGWPoettlerMSchmidingerM, et al
CD98hc (SLC3A2), a novel marker in renal cell cancer. Eur J Clin Invest
2009; 39: 304–310.19292886,
PragerGWPoettlerMSchmidingerM, et al
CD98hc (SLC3A2), a novel marker in renal cell cancer. Eur J Clin Invest
2009; 39: 304–310.19292886
-
(
BaisCMuellerBBradyMF, et al
Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses. J Natl Cancer Inst
2017; 109: djx066.)
BaisCMuellerBBradyMF, et al
Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses. J Natl Cancer Inst
2017; 109: djx066.
BaisCMuellerBBradyMF, et al
Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses. J Natl Cancer Inst
2017; 109: djx066.,
BaisCMuellerBBradyMF, et al
Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses. J Natl Cancer Inst
2017; 109: djx066.
-
The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases
-
(
RajaganeshanRPrasadRGuillouPJ, et al
The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases. Br J Cancer
2007; 96: 1112–1117.17353920)
RajaganeshanRPrasadRGuillouPJ, et al
The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases. Br J Cancer
2007; 96: 1112–1117.17353920
RajaganeshanRPrasadRGuillouPJ, et al
The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases. Br J Cancer
2007; 96: 1112–1117.17353920,
RajaganeshanRPrasadRGuillouPJ, et al
The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases. Br J Cancer
2007; 96: 1112–1117.17353920
-
(
ZygonJSzajewskiMKruszewskiWJ, et al
VEGF, Flt-1, and microvessel density in primary tumors as predictive factors of colorectal cancer prognosis. Mol Clin Oncol
2017; 6: 243–248.28357103)
ZygonJSzajewskiMKruszewskiWJ, et al
VEGF, Flt-1, and microvessel density in primary tumors as predictive factors of colorectal cancer prognosis. Mol Clin Oncol
2017; 6: 243–248.28357103
ZygonJSzajewskiMKruszewskiWJ, et al
VEGF, Flt-1, and microvessel density in primary tumors as predictive factors of colorectal cancer prognosis. Mol Clin Oncol
2017; 6: 243–248.28357103,
ZygonJSzajewskiMKruszewskiWJ, et al
VEGF, Flt-1, and microvessel density in primary tumors as predictive factors of colorectal cancer prognosis. Mol Clin Oncol
2017; 6: 243–248.28357103
-
FDA approves bevacizumab biosimilar for five cancer types
-
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature
-
(
NegriFVBozzettiCLagrastaCA, et al
PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer
2010; 102: 162–164.19953097)
NegriFVBozzettiCLagrastaCA, et al
PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer
2010; 102: 162–164.19953097
NegriFVBozzettiCLagrastaCA, et al
PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer
2010; 102: 162–164.19953097,
NegriFVBozzettiCLagrastaCA, et al
PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer
2010; 102: 162–164.19953097